The foundation behind Novo Nordisk, which makes weight-loss drugs Ozempic and Wegovy, will invest €80 million ($93 million) ...

Danish pharmaceutical company Novo Nordisk has officially launched its once-weekly injectable weight management drug, Wegovy® ...

Novo Nordisk has today launched its weight-loss injection Wegovy in Britain, its second debut in Europe in just over a month as the drugmaker seeks to expand in the region even as it struggles to ...

Novo Nordisk stated: “While 90% of patients taking Wegovy have a co-pay of $0 to $25 per month, this offer was designed to support cash-paying patients without insurance coverage.

Diabetes and obesity drug developer Novo Nordisk on Thursday significantly raised its full-year operating profit and sales expectations on the back of strong demand for its highly popular Wegovy ...

Biopharmaceutical company Biocon is planning to submit a request for approval of generic copies of the blockbuster ...

Novo Nordisk has launched a new online pharmacy, NovoCare, where it will offer its weight-loss drug Wegovy at less than half its usual price. As Europe’s biggest pharmaceutical company, Novo ...

In an echo of the pattern laid last year, following a record-high outlay at the very beginning of the year, TV drug ad ...

NVO shares fall 19.9% year to date amid weak CagriSema data, CEO exit and rising pressure from rivals in obesity care.

Novo Nordisk A/S (NYSE:NVO) ranks among the best set-it-and-forget-it stocks to buy. Novo Nordisk A/S (NYSE:NVO) announced on ...

Novo Nordisk has today forecast another year of double-digit record sales and operating profit growth as it began easing restrictions on supply of its popular weight-loss drug Wegovy.

Weight Watchers is Novo Nordisk's latest partnersip.